2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1696

Score Classification Underestimates the Real Cardiovascular Risk in Psoriatic Arthritis Patients
Abstract Number: 2451

Scoring Medication Requirements and Side-Effects in Juvenile Idiopathic Arthritis: Perspectives of Patients, Parents and Clinicians
Abstract Number: 3139

Screening Algorithm for Pulmonary Hypertension in Systemic Sclerosis – Comparison of Predictive Accuracy of Three Algorithms
Abstract Number: 307

Screening for Pulmonary Hypertension in the Anti-Synthetase Syndrome; Utility of Four Different Screening Approaches
Abstract Number: 1521

Screening for Urinary Tract Infection in Rheumatoid Arthritis Patients Treated with TNF-Inhibitors in the Daily Clinic
Abstract Number: 2625

SDAI 50 Is More Stringent Than the EULAR Response Measure and a Better Predictor of Low Disease State/Remission in Early Rheumatoid Arthritis: Results from an Early Arthritis Cohort
Abstract Number: 245

Seasonal Variation in Acute Gouty Arthritis: Data from Nationwide Inpatient Sample
Abstract Number: 855

Seasonality in ANCA-Associated Vasculitis
Abstract Number: 2159

Second Temporal Artery Biopsies in Patients with Temporal Arteritis (TA)
Abstract Number: 2757

Secondary Efficacy Endpoints: Results from a Phase 3 Study Comparing ABP 501 with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 912

Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis
Abstract Number: 2853

Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial
Abstract Number: 2148

Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: 2890

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis in Anti-TNF-Naïve Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials
Abstract Number: 2896

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].